Schrier RW, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099−2112. doi: 10.1056/NEJMoa065181

• PubMed
Schrier RW, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099−2112. doi: 10.1056/NEJMoa065181)| false
• Search Google Scholar
• Export Citation

Berl T, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705−712. doi: 10.1681/ASN.2009080857. Erratum in: J Am Soc Nephrol 2010; 21:1407. https://jasn.asnjournals.org/content/21/8/1407.2

• PubMed
Berl T, Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705−712. doi: 10.1681/ASN.2009080857. Erratum in: J Am Soc Nephrol 2010; 21:1407. https://jasn.asnjournals.org/content/21/8/1407.2)| false
• Search Google Scholar
• Export Citation

Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407−2418. doi: 10.1056/NEJMoa1205511

• PubMed
Torres VE, Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367:2407−2418. doi: 10.1056/NEJMoa1205511)| false
• Search Google Scholar
• Export Citation

Torres VE, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377:1930−1942. doi: 10.1056/NEJMoa1710030

• PubMed
Torres VE, Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 2017; 377:1930−1942. doi: 10.1056/NEJMoa1710030)| false
• Search Google Scholar
• Export Citation

Edwards ME, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2018; 13:1153−1161. doi: 10.2215/CJN.01520218

• PubMed
Edwards ME, Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2018; 13:1153−1161. doi: 10.2215/CJN.01520218)| false
• Search Google Scholar
• Export Citation

Malhotra I, et al. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: Case review on role of vaptans. Case Rep Endocrinol 2014; 2014:807054. doi: 10.1155/2014/807054

• PubMed
Malhotra I, Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: Case review on role of vaptans. Case Rep Endocrinol 2014; 2014:807054. doi: 10.1155/2014/807054)| false
• Search Google Scholar
• Export Citation

Sterns RH. Tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone: Is the dose too high? Am J Kidney Dis 2018; 71:763−765. doi: 10.1053/j.ajkd.2018.02.355

• PubMed
Sterns RH. Tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone: Is the dose too high? Am J Kidney Dis 2018; 71:763−765. doi: 10.1053/j.ajkd.2018.02.355)| false
• Search Google Scholar
• Export Citation

Erickson KF, et al. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013; 159:382−389. doi: 10.7326/L14-5001-7

• PubMed
Erickson KF, Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med 2013; 159:382−389. doi: 10.7326/L14-5001-7)| false
• Search Google Scholar
• Export Citation

Jamookeeah C, et al. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord 2016; 16:22. doi: 10.1186/s12902-016-0104-z

• PubMed
Jamookeeah C, Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocr Disord 2016; 16:22. doi: 10.1186/s12902-016-0104-z)| false
• Search Google Scholar
• Export Citation

Chebib FT, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018; 29:2458−2470. doi: 10.1681/ASN.2018060590

• PubMed
Chebib FT, A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol 2018; 29:2458−2470. doi: 10.1681/ASN.2018060590)| false
• Search Google Scholar
• Export Citation

Gross P, et al. Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers? Nephrol Dial Transplant 2019; 34:35−37. doi: 10.1093/ndt/gfy298

• PubMed
Gross P, Con: Tolvaptan for autosomal dominant polycystic kidney disease—do we know all the answers? Nephrol Dial Transplant 2019; 34:35−37. doi: 10.1093/ndt/gfy298)| false
• Search Google Scholar
• Export Citation

Meijer E, Gansevoort RT. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: Efficacy, safety, and tolerability. Kidney Int 2020; 98:289−293. doi: 10.1016/j.kint.2020.03.023

• PubMed
Meijer E, Gansevoort RT. Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: Efficacy, safety, and tolerability. Kidney Int 2020; 98:289−293. doi: 10.1016/j.kint.2020.03.023)| false
• Search Google Scholar
• Export Citation

Gordon CE, Perrone RD. Tolvaptan or transplant: Why wait? Kidney Int 2020; 98:286−289. doi:10.1016/j.kint.2020.03.022.Erratum in: Kidney Int 2020; 98:1622. doi: 10.1016/j.kint.2020.11.002

• PubMed
Gordon CE, Perrone RD. Tolvaptan or transplant: Why wait? Kidney Int 2020; 98:286−289. doi:10.1016/j.kint.2020.03.022.Erratum in: Kidney Int 2020; 98:1622. doi: 10.1016/j.kint.2020.11.002)| false
• Search Google Scholar
• Export Citation